Portal de Periódicos da CAPES

Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination

2014; John Libbey Eurotext; Volume: 24; Issue: 1 Linguagem: Inglês

10.1684/ejd.2013.2213

1952-4013

Olivier Join‐Lambert, Florence Ribadeau-Dumas, Vincent Jullien, Marie-Dominique Kitzis, Jean-Philippe Jaı̈s, Hélène Coignard-Biehler, Hélène Guet‐Revillet, Paul‐Henri Consigny, M. Delage, Xavier Nassif, Olivier Lortholary, Aude Nassif,

Chemotherapy-related skin toxicity

The oral clindamycin-rifampin combination is a treatment option of hidradenitis suppurativa (HS) [1–3]. The following report suggests that a significant pharmacokinetic interaction exists between the two drugs that may alter the efficacy of the treatment.In July 2007, the clindamycin and rifampin plasma concentrations were measured in a 26-year-old HS patient who did not respond to a standard dosing regimen of clindamycin (20-40 mg/kg/day, tid) and rifampin (20 mg/kg/day, bid). The trough level [...]